Jeremie Guedj

• 
  Ebola Viral Dynamics in NHPs
  Jeremie Guedj

  I will discuss our recent contributions to the field of Ebola virus and the evaluation of favipiravir, a nucleotide analogue initially approved for severe Influenza in Japan. I will show how the techniques of viral dynamics have been used throughout this project, first to find a relevant dosing regimen in humans infected with Ebola virus during the last 2014-2015 outbreak, then to optimize its efficacy using studies in Non-Human Primates. Lastly, I will discuss the use of modeling to better understand the roles of the innate and adaptive immune response in the pathogenesis and the clearance of the infection, as well as the potential application of favipiravir to other viral infections.